Vertex Pharmaceutical (VRTX +0.7%) says data from its follow-up study of Kalydeco was positive. Tests showed improvements in lung function, respiratory symptoms and weight gain among people who were treated with the drug for 48 weeks in one of two pivotal studies, and were durable for up to 96 total weeks of treatment.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs